文献速递外周动脉疾病

旋切术治疗日本外周动脉疾病股腘病变的安全性与疗效:J-SUPREME与J-SUPREME II试验

Clinical Safety and Efficacy of Rotational Atherectomy in Japanese Patients with Peripheral Arterial Disease Presenting Femoropopliteal Lesions: The J-SUPREME and J-SUPREME II Trials.
PubMed 文献 · J Endovasc Ther · 2021-09-13

J-SUPREME和J-SUPREME II是两项前瞻性、多中心、单臂临床试验,评估Jetstream旋切系统治疗日本症状性股浅动脉和/或近端腘动脉狭窄或闭塞病变的表现。J-SUPREME中患者接受旋切后普通球囊扩张,J-SUPREME II中接受旋切后药物涂层球囊治疗。结果显示两试验均无 bailout 支架或旁路转流,1个月内无主要不良事件;6个月一期通畅率分别为40.4%和96.7%,Rutherford分级改善至少1级的比例分别为79.2%和100%。

要点

  • 旋切后DCB治疗6个月一期通畅率达96.7%,显著高于旋切后普通球囊的40.4%。
  • 两试验均无 bailout 支架或旁路转流,1个月内无主要不良事件。
  • J-SUPREME II中77.4%病变为PACSS 4级严重钙化,仍获得高通畅率。

核心结论

  • J-SUPREME试验证明Jetstream旋切系统的手术安全性和有效性,J-SUPREME II显示旋切联合DCB治疗后6个月通畅率持续。

研究设计与样本

  • J-SUPREME和J-SUPREME II均为前瞻性、多中心、单臂临床试验。
  • J-SUPREME纳入50例患者,J-SUPREME II纳入31例患者,均为Rutherford 2、3或4级,股浅动脉和/或近端腘动脉狭窄≥70%的病变。
  • J-SUPREME中病变需为钙化,J-SUPREME II中病变需为严重钙化;J-SUPREME患者接受旋切后PTA,J-SUPREME II患者接受旋切后DCB。

主要发现

  • J-SUPREME患者平均年龄72.3±8.7岁,病变长度82.0±41.5 mm,钙化PACSS 3级占36%,4级占22%。
  • J-SUPREME II患者平均年龄72.5±7.7岁,病变长度122.6±55.6 mm,钙化PACSS 3级占19.4%,4级占77.4%。
  • 两试验均无需 bailout 支架或旁路转流,1个月内无主要不良事件报告。
  • J-SUPREME 6个月一期通畅率为40.4%(19/47),J-SUPREME II为96.7%(29/30)。
  • 6个月时J-SUPREME中79.2%(38/48)患者Rutherford分级改善至少1级,J-SUPREME II中为100%(30/30)。

关键数值与推荐

  • J-SUPREME 6个月一期通畅率40.4%(19/47),J-SUPREME II 6个月一期通畅率96.7%(29/30)。
  • J-SUPREME 6个月Rutherford分级改善至少1级比例79.2%(38/48),J-SUPREME II为100%(30/30)。

临床怎么用

  • 对于股腘动脉钙化病变,旋切后联合DCB可能获得比旋切后普通球囊更高的6个月通畅率。
  • 旋切系统在严重钙化病变中未需 bailout 支架,短期安全性良好。

局限性

  • 两项均为单臂试验,无对照组,样本量较小(50例和31例)。
  • 随访时间仅至6个月,缺乏长期疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of the J-SUPREME (J-S) and J-SUPREME II (J-SII) trials was to evaluate the performance of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in the superficial femoral and popliteal arteries. MATERIALS AND METHODS: The J-S and J-SII trials were both prospective, multicenter, single-arm clinical trials. Patients in J-S underwent Jetstream atherectomy followed by percutaneous transluminal angioplasty (PTA), whereas those in J-SII had adjunctive drug-coated balloon (DCB) treatment following atherectomy. Patients were adults with Rutherford category 2, 3, or 4 and had stenotic, restenotic, or occlusive lesion(s) with a degree of stenosis ≥70 in the superficial femoral artery and/or proximal popliteal artery. In J-S, lesions were required to be calcified, and in J-SII lesions were required to be severely calcified. RESULTS: A total of 50 patients were enrolled in J-S (mean age 72.3±8.7 years, lesion length 82.0±41.5 mm, 36% calcification PACSS Grade 3, 22% Grade 4) and 31 patients in J-SII (mean age 72.5±7.7 years, lesion length 122.6±55.6 mm, 19.4% calcification PACSS Grade 3, 77.4% Grade 4). No bailout stenting or bypass conversions were required. No major adverse events (MAEs) were reported for either trial through 1 month. The 6-month primary patency for J-S, with PTA alone following atherectomy, was 40.4% (19/47). The 6-month primary patency for J-SII, with DCB treatment following atherectomy, was 96.7% (29/30). At 6-month post-procedure, 79.2% (38/48) of patients in J-S, and 100% (30/30) of patients in J-SII had improved by at least 1 Rutherford category. CONCLUSION: J-SUPREME trial results demonstrate procedural safety and efficacy of the Jetstream Atherectomy System and J-SII showed sustained patency through 6 months following combination treatment with Jetstream atherectomy and DCB.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Iida O, Urasawa K, Shibata Y, et al. Clinical Safety and Efficacy of Rotational Atherectomy in Japanese Patients with Peripheral Arterial Disease Presenting Femoropopliteal Lesions: The J-SUPREME and J-SUPREME II Trials. J Endovasc Ther. 2021. PMID: 34510954. doi:10.1177/15266028211045700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。